Ankita Redla, President of KCL Oncology Society, shared a post on LinkedIn :
“I am delighted to share that I was selected to present my abstracts at the International Urological Cancer Summit (IUCS) on 4–5 September 2025 in Portsmouth, UK.
This year’s summit brought together participants from over 100 countries, with inspiring talks from world leaders in the field of urological oncology.
It was a privilege to work alongside Sneha Mehrotra, with one of our abstracts being shortlisted as a finalist and included in the poster discussion, as well as being awarded a travel grant. A special thank you to Aruni Ghose for his invaluable mentorship and guidance throughout this work.
Our research focused on the role of circulating tumour DNA (ctDNA) in metastatic urothelial cancer, as well as biomarkers detecting minimal residual disease for predicting relapse in operable disease. I am excited to explore this field further as biomarkers and ctDNA represent the future of personalised oncology, holding promise for earlier detection, better risk stratification, and more precise treatment strategies.
Our abstracts have also been published in The Oncologist (Oxford University Press).”
Title: Biomarkers detecting minimal residual disease for predicting risk of relapse in operable urothelial cancer: a systematic review and meta-analysis of phase II/III clinical trials
Authors: A C Redla, S Mehrotra, J K Tan, A Ghose, A Shah, P Kotecha, A Sharma, P Das, J Teoh, N Vasdev.
Read the full article at The Oncologist .
Title: Correlation of circulating tumor DNA with oncological endpoints in metastatic urothelial cancer: a systematic review and meta-analysis of phase II/III clinical trials
Authors: S Mehrotra, A C Redla, J K Tan, A Ghose, A Maniam, S Boussios, G L Banna, P Das, S Adeleke, A Sharma
Read the full article at The Oncologist .
More Posts featuring IUCS 2025.